OptiBiotix Health PLC Supply agreement for LPLDL® in the Baltic States (2939P)
February 07 2019 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 2939P
OptiBiotix Health PLC
07 February 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Supply agreement for LP(LDL) (R) in the Baltic States
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its 100% owned subsidiary, ProBiotix
Health Ltd, has entered into a three-year supply agreement with
Biolat JSC ("Biolat") covering the supply of its cholesterol and
blood pressure reducing LP(LDL) (R) strain in Estonia, Latvia and
Lithuania.
The agreement grants Biolat a non-exclusive license to package
and commercialise own label capsular food products featuring
OptiBiotix's proprietary strain Lactobacillus plantarum LP(LDL)
(R), with a view to maximising the financial return for both
parties. It also provides mutual commercial commitment with ongoing
revenue and reflects the growing confidence in the science behind
LP(LDL) (R) as a functional ingredient, as well as the growing
demand for science based food supplement products in the Eastern
European market.
Biolat has over 25 years' experience in the manufacturing and
distribution of high quality and scientifically validated
innovative natural products. Based in Latvia, it is one of the
leading players in pharmacy distribution of these products in the
Baltics region.
According to Eurostat (2018), the Baltic Member States record
the highest death rates from diseases of the circulatory system in
the entire EU, with cardiovascular-related fatalities accounting
for 50-60% of all deaths. This is also one of the regions where
females have the greatest cardiovascular risk - the proportions of
women dying from this cause are up to 20% higher than those for
men.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce this supply agreement with Biolat, which further
reinforces the presence of the LP(LDL) (R) in a wide range of
products in Eastern Europe, where heart disease is a major public
health issue. We decided to partner up with Biolat for their
experience in the field of natural products manufacturing and
distribution and their knowledge of this geographic area. They also
have an outstanding track record of successful product launches
leading to long-term revenue generation and growth."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBUGDDGUGBGCL
(END) Dow Jones Newswires
February 07, 2019 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024